Bruce Cheson, MD Assumes Chairmanship of Lymphoma Research Foundation Scientific Advisory Board

June 30, 2010

The Lymphoma Research Foundation (LRF) has announced the election of Bruce Cheson, MD, F.A.C.P., professor of Medicine and director of Hematology as the chair of its Scientific Advisory Board (SAB). Cheson’s two-year term as begins July 1, 2010.

“We are pleased to have Dr. Cheson take on this important role,” said LRF chief executive officer Diane Blum, MSW. “He has generously given of his time to the Foundation for many years, holding a variety of leadership roles and bringing a wealth of experience to the position. He is a visionary leader, and his insight and skills will prove invaluable.”

Cheson's clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies. He has authored over 300 medical publications and abstracts and is a member of numerous editorial boards. Currently, Cheson serves as Editor-in-Chief of both Clinical Lymphoma, Myeloma & Leukemia and Clinical Advances in Hematology and Oncology.

Previously, he served as Head of the Medicine Section for the National Cancer Institute's (NCI) Clinical Investigations Branch within the Cancer Therapy Evaluation Program, and senior staff physician in the NCI's Lymphoma Clinic. Prior to that, Cheson was assistant professor of medicine in Hematology/Oncology at the University of Utah.

“It is an honor to accept the role of Chair of the Lymphoma Research Foundation Scientific Advisory Board,” said Cheson. “Working with my colleagues on the SAB and the Foundation’s dedicated board of directors, I am confident we will continue to advance the field of lymphoma research and the Lymphoma Research Foundation’s mission.”

Comprised of the world’s leading lymphoma researchers and oncologists, the SAB formulates the Foundation’s research portfolio, seeking out the most innovative and promising lymphoma research projects for support. The 40-member SAB reviews grant proposals and makes recommendations regarding research priorities and funding to the LRF board of directors. The SAB also evaluates the progress of on-going research projects and guides the strategic direction of the Foundation’s research programs and consortia.

The Lymphoma Research Foundation (LRF) is the nation's largest non-profit lymphoma organization devoted to funding innovative research and providing people with lymphoma and healthcare professionals with critical information on the disease. To date, LRF has funded over $40 million in lymphoma-specific research. For additional information on LRF’s programs and services, visit www.lymphoma.org.
 

Author: Meghan Gutierrez
-->